龍8體育

History of Kyowa KirinLearn more about our heritage and
contributions to healthcare

Kyowa Kirin is a pharmaceutical company,
formed from a combination of the depth of
experience
and strong business record of
龙8体育 Kyowa Hakko Kogyo and Kirin Pharma.

Find out the combined histories of Kyowa
Hakko Kogyo and Kirin Pharma, followed by the history
of Kyowa Kirin,
touching upon their
performance in the field of research and
龙8体育 development to date.

1907

Establishment of Kirin Brewery Co., Ltd.

Kirin Brewery Co., Ltd.

1949

Establishment of Kyowa Hakko Kogyo Co., Ltd. as a secondary company of Kyowa Sangyo Co., Ltd, as part of industrial readjustment plans.

Kyowa Hakko Kogyo Co., Ltd.

1951

龙8体育Introduced production technology of Streptomycin, an anti-tubercular drug, from US pharmaceutical company Merck & Co., Inc. and succeeded in its mass production. Contributed to the wiping out of tuberculosis in Japan (beginning of involvement in pharmaceutical business operations).

Lapping bus for commerce of Streptomycin

1956

Success of isolation and commercially mass-production of the anticancer drug, Mitomycin C.

龙8体育Invention of the process of L-glutamic acid production by fermentation (a world first).

1963

Initiation of full-scale involvement in the pharmaceutical business.

Release of Mitomycin C, an anticancer drug, and Spiramycin, an antibiotic drug.

1967

Release of 5-FU, an anticancer drug.

1971

Release of Leunase, an anticancer drug.

1982

龙8体育The Research Institute for Production Development foundation begins full-scale research towards the commercialization of erythropoietin.

1988

龙8体育Supported the establishment in the U.S.A. of the La Jolla Institute for Allergy and Immunology (LIAI).

La Jolla Institute

1990

龙8体育elease of ESPO?, an erythropoietin (EPO) drug.

1991

龙8体育Release of GRAN?, G-CSF drug.

Release of Coniel, a remedy for hypertension and agina pectoris.

2003

龙8体育Establishment of BioWa, Inc. in the United States to promote Kyowa Hakko's therapeutic antibody business.

2007

龙8体育The launch of Kirin Pharma Company, Limited to accompany the adoption by Kirin Brewery Company, Limited of a pure holding company system. Release of NESP?, a long-acting erythropoietic stimulating drug.

Established COMPLEGENT?, a novel antibody engineering technology that enhances the efficacy of antibodies, and licensed to BioWa, Inc, its subsidiary.

龙8体育Capital alliance between Kyowa Hakko Group and Kirin Group.

2008

Release of REGPARA?, a drug for secondary hyperparathyroidism.

龙8体育Spun off its biochemical business, establishing Kyowa Hakko Bio Co., Ltd.

龙8体育Kyowa Hakko Kirin was formed through the merger of Kyowa Hakko Kogyo and Kirin Pharma.

2009

龙8体育Introduced "Commitment to Life".

2011

Acquired ProStrakan Group plc.

2012

龙8体育Launch of Poteligeo? in Japan, a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL)

2013

龙8体育Launch of NOURIAST? tablets 20 mg in Japan, a novel antiparkinsonian agent.

2014

龙8体育ProStrakan Completes Acquisition of Archimedes.

Launch of Sustained-Duration G-CSF Product G-LASTA? in Japan.

2016

Rebranding Western Pharmaceutical Subsidiaries to "Kyowa Kirin".

Launch of LUMICEF? for Psoriasis Treatment in Japan.

2018

龙8体育Crysvita? approved in the US and Europe, sales to start as a treatment for patients with X-linked hypophosphatemia.

Poteligeo? approved in the US and Europe as a treatment for mycosis fungoides (MF) and Sézary syndrome (SS).

2019

龙8体育Trade name changed to current "Kyowa Kirin Co., Ltd." from Kyowa Hakko Kirin Co., Ltd.

龙8体育Crysvita? launched in Japan for the treatment of FGF23-related Hypophosphatemic Rickets and Osteomalacia.

龙8体育Nourianz? launched in the US for use in Parkinson's disease.

CI logo of Kyowa Kirin
北京快乐8实时开奖